MARSHALL WACE, LLP - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBER and the CUSIP is G46843101. A total of 49 filers reported holding IBERE PHARMACEUTICALS in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$5,446,653
+1.8%
539,8070.0%0.01%0.0%
Q3 2022$5,351,000
+2.5%
539,807
+1.4%
0.01%
+9.1%
Q2 2022$5,220,0000.0%532,1850.0%0.01%
+10.0%
Q1 2022$5,220,000
+1.0%
532,185
+0.2%
0.01%0.0%
Q4 2021$5,166,000
+18.5%
531,385
+18.1%
0.01%
-44.4%
Q3 2021$4,360,000
+0.2%
449,9940.0%0.02%
-10.0%
Q2 2021$4,351,000449,9940.02%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q1 2022
NameSharesValueWeighting ↓
Integrity Capital Management (HK) Ltd 46,717$458,0002.36%
Lynwood Capital Management Inc. 51,400$504,0000.54%
TEGEAN CAPITAL MANAGEMENT, LLC 91,422$896,0000.48%
KRYGER CAPITAL Ltd 422,029$4,140,0000.24%
BASSO CAPITAL MANAGEMENT, L.P. 170,114$1,669,0000.16%
SPRING CREEK CAPITAL LLC 400,000$3,924,0000.16%
Vestcor Inc 400,000$3,924,0000.14%
Castle Creek Arbitrage, LLC 253,446$2,483,0000.12%
ROBINSON CAPITAL MANAGEMENT, LLC 17,881$175,0000.12%
Knott David M Jr 36,000$353,0000.11%
View complete list of IBERE PHARMACEUTICALS shareholders